Biomedical subjects
Publications and source records attributed to E Flückiger.
Prolactin secretion inhibition and changes in striatal dopamine metabolism in rats were compared after the administration of 8 alpha-amino-ergoline CH 29-717 and 2 derivates. CQ 32-084 was similar to but less potent than CH 29-717, while 32-085, the l-methyl derivative, showed delayed dopaminomimetic effects.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The effects of bromocriptine on the secretion of prolactin, gonadotrophins, thyretrophin (TSH), corticotrophin (ACTH), somatotrophin (GH) and melanocyte-stimulating hormone (MSH) in mammals are presented and the sites and mode of action briefly discussed.
Bromocriptine lowers blood pressure in animals and in man. Results obtained in experiments performed in the dog and cat suggest three possible mechanisms of action: a) relaxation of vascular smooth muscle, principally in splanchnic and renal vessels, (b) inhibition of transmitter release from noradrenergic nerve endings, (c) central inhibition of sympathetic nerve activity. The effect of bromocriptine at each putative site of action can be explained in terms of dopamine receptor stimulation.
A brief summary is given about present-day knowledge and views on the control of prolactin secretion in mammals. This is followed by the presentation of the evidence that dopamine is the inhibitory hypothalamic transducer controlling hormone release by prolactin cells. Most of the evidence is pharmacological in nature. It is only very recently that dopamine has been found in a meaningful concentration in the blood flowing from the median eminence to the pituitary. Although the dopamine concept of an inhibitory control of prolactin secretion seems quite satisfactory, the possibility of another unrelated inhibitory control system is not excluded.